Evidence map›Paper›PMID 36419396›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2022

[Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].

Jieqiong Wu, Dunqiang Ren, Huanhuan Bi, Bingqian Yi, Hongmei Wang

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jieqiong WuDepartment of Respiratory and Critical Care Medcine, The Affiliated Hospital of Qingdao University.
Dunqiang RenDepartment of Respiratory and Critical Care Medcine, The Affiliated Hospital of Qingdao University.
Huanhuan BiSchool of Medicine Qingdao University, Qingdao 266000, China.
Bingqian YiDepartment of Respiratory and Critical Care Medcine, The Affiliated Hospital of Qingdao University.
Hongmei WangDepartment of Respiratory and Critical Care Medcine, The Affiliated Hospital of Qingdao University.
Affiliated Hospital of Qingdao University · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is a newly discovered immune checkpoint molecule, mainly expressed on the surface of T cells and natural killer (NK) cells. By binding to cluster of differentiation 155 (CD155) and other ligands, it inhibits T cell and NK cell-mediated immune responses and affects the tumor microenvironment. Multiple preclinical studies have demonstrated that the TIGIT/CD155 pathway plays a role in a variety of solid and hematological tumors. Clinical trials investigating TIGIT inhibitors alone or in combination with programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors for lung cancer are currently underway.
.

Indexed as

Lung NeoplasmsHumansImmunologic FactorsImmunotherapyReceptors, ImmunologicThoraxTumor MicroenvironmentImmunologic FactorsReceptors, ImmunologicTIGIT protein, humanImmunotherapyLung neoplasmsPD-L1TIGIT

Identifiers

PMID36419396
PMCPMC9720676
OpenAlexW4310330452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.